Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Slimthru is a weight management dietary supplement developed by the Dutch company DSM. It is formulated as a liquid emulsion containing a proprietary blend of oat oil and palm oil. The product's mechanism of action is based on the 'ileal brake' effect; the specific lipid structure is designed to resist early digestion in the stomach and proximal small intestine, allowing the oils to reach the ileum. The presence of these undigested lipids in the distal small intestine triggers the release of satiety hormones, which prolongs the sensation of fullness and suppresses appetite, ultimately leading to reduced daily calorie intake. Slimthru was marketed as a 'shot' that could be consumed directly or mixed with various foods and beverages like yogurt, coffee, or tea. Its commercial availability has become limited in recent years, suggesting it is no longer actively marketed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Slimthru.